Fashanu Oluwaseun E, Heckbert Susan R, Aguilar David, Jensen Paul N, Ballantyne Christie M, Basu Saonli, Hoogeveen Ron C, deFilippi Christopher, Cushman Mary, Folsom Aaron R
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA, USA.
Res Pract Thromb Haemost. 2017 Oct;1(2):223-230. doi: 10.1002/rth2.12038. Epub 2017 Sep 4.
The inflammatory biomarker galectin-3 contributes to pathologic conditions such as heart failure and stimulates murine thrombogenesis. Its association with venous thromboembolism (VTE) has been sparsely studied.
To assess the prospective association of plasma galectin-3 and the rs4644 SNP with VTE incidence.
We measured plasma galectin-3 in 9,916 participants in the Atherosclerosis Risk in Communities (ARIC) study cohort in 1996 - 1998 and identified VTEs through 2013. Using Cox regression, we estimated the hazard ratio associating galectin-3 with incident VTE over a median of 13.9 years. Replication was sought in the Cardiovascular Health Study (CHS).
ARIC included 21.8% blacks and 56.2% females with mean baseline age of 62.7 years. The incidence rate of VTE (n=389 events) increased across quintiles of galectin-3, with hazard ratios (95% CI) of 1 (reference), 1.13 (0.80 - 1.61), 1.00 (0.70 - 1.43), 1.36 (0.96 - 1.91), and 1.55 (1.09 - 2.19) (p-trend = 0.005), adjusted for age, sex, race, body mass index, diabetes status, and renal function. Results did not replicate in the CHS (124 VTE), but meta-analysis of both studies yielded a pooled hazard ratio (95% CI) for 1 SD increment in log galectin-3 of 1.10 (1.00 - 1.22). In ARIC, the C allele of rs4644 in the gene was associated with higher galectin-3 level, and in whites, with an increased rate of VTE.
Galectin-3 levels were associated positively with VTE incidence.
炎症生物标志物半乳糖凝集素-3与心力衰竭等病理状况相关，并可刺激小鼠血栓形成。其与静脉血栓栓塞症（VTE）的关联研究较少。
评估血浆半乳糖凝集素-3及rs4644单核苷酸多态性（SNP）与VTE发病率的前瞻性关联。
我们于1996 - 1998年在社区动脉粥样硬化风险（ARIC）研究队列的9916名参与者中测量了血浆半乳糖凝集素-3，并在2013年前确定了VTE病例。使用Cox回归分析，我们估计了在13.9年的中位数时间里，半乳糖凝集素-3与VTE发病的风险比。在心血管健康研究（CHS）中进行了重复验证。
ARIC研究队列中包括21.8%的黑人及56.2%的女性，平均基线年龄为62.7岁。VTE发病率（n = 389例）随半乳糖凝集素-3五分位数升高而增加，校正年龄、性别、种族、体重指数、糖尿病状态和肾功能后，风险比（95%可信区间）分别为1（对照）、1.13（0.80 - 1.61）、1.00（0.70 - 1.43）、1.36（0.96 - 1.91）和1.55（1.09 - 2.19）（p趋势 = 0.005）。结果在CHS（124例VTE）中未得到重复验证，但两项研究的荟萃分析显示，对数半乳糖凝集素-3每增加1个标准差，合并风险比（95%可信区间）为1.10（1.00 - 1.22）。在ARIC研究中，该基因中rs4644的C等位基因与较高的半乳糖凝集素-3水平相关，在白人中与VTE发生率增加相关。
半乳糖凝集素-3水平与VTE发病率呈正相关。
